Takeda settles Actos damages case for $2.7bnTakeda has agreed to pay an eye-watering $2.7 billion to settle claims that its diabetes drug Actos caused Share XTakeda settles Actos damages case for $2.7bnhttps://pharmaphorum.com/news/takeda-settles-actos-damages-case-for-2-7bn/
Merrimack hoping for first product approval this yearThe US FDA has accepted Merrimack’s rolling application to market its first product, the second-line pancreatic cancer therapy Share XMerrimack hoping for first product approval this yearhttps://pharmaphorum.com/news/merrimack-hoping-for-first-product-approval-this-year/
Opdivo set to be first PD-1 approved in EuropeBristol-Myers Squibb’s (BMS) new cancer immunotherapy Opdivo has been recommended by Europe’s CHMP committee – just one step Share XOpdivo set to be first PD-1 approved in Europehttps://pharmaphorum.com/news/opdivo-set-to-be-first-pd-1-approved-in-europe/
AZ’s Celgene tie-up ‘will boost immuno-oncology business’AstraZeneca (AZ) has forged an alliance with Celgene to accelerate the development of its checkpoint inhibitor MEDI4736 in Share XAZ’s Celgene tie-up ‘will boost immuno-oncology business’https://pharmaphorum.com/news/azs-celgene-tie-up-will-boost-immuno-oncology-business/
AstraZeneca: UK medicines deal not deliveringThe head of AstraZeneca in the UK says the country’s deal on paying pharma for medicines is not Share XAstraZeneca: UK medicines deal not deliveringhttps://pharmaphorum.com/news/astrazeneca-uk-medicines-deal-not-delivering/
AbbVie sticking to HCV sales forecastsAbbVie’s combination hepatitis C virus (HCV) therapy Viekira Pak racked up sales of $231 million in its first Share XAbbVie sticking to HCV sales forecastshttps://pharmaphorum.com/news/abbvie-sticking-to-hcv-sales-forecasts/
Boehringer hopes for new product boost after challenging 2014Boehringer Ingelheim (BI) has been reflecting on a challenging 2014 as currency-adjusted sales dipped 3.2 per cent to Share XBoehringer hopes for new product boost after challenging 2014https://pharmaphorum.com/news/boehringer-hopes-for-new-product-boost-after-challenging-2014/
TiGenix on track for pivotal cell therapy results in Crohn’sCell therapy specialist TiGenix is mere months away from reporting phase III trial results for its fistulising Crohn’s Share XTiGenix on track for pivotal cell therapy results in Crohn’shttps://pharmaphorum.com/news/tigenix-on-track-for-pivotal-cell-therapy-results-in-crohns/
Renaissance for Pfizer antibody-drug conjugate?Pfizer has scored a phase III trial success for its antibody-drug conjugate (ADC) inotuzumab ozogamicin in acute lymphoblastic Share XRenaissance for Pfizer antibody-drug conjugate?https://pharmaphorum.com/news/renaissance-for-pfizer-antibody-drug-conjugate/
